Chinese clinical oncology最新文献

{"title":"Preliminary study on efficacy and safety of pixantrone in relapsed/refractory aggressive B-cell lymphomas: multicenter, retrospective cohort study by Polish Lymphoma Research Group (PLRG).","authors":"Magdalena Witkowska, Senastin Szmit, Agnieszka Kołkowska-Leśniak, Bartłomiej Kuszczak, Renata Kasza, Anna Koclęga, Oliwia Bachanek-Mitura, Dariusz Wołowiec","doi":"10.21037/cco-2026-1-0026","DOIUrl":"https://doi.org/10.21037/cco-2026-1-0026","url":null,"abstract":"<p><strong>Background: </strong>Pixantrone (PIX) is an anthracycline derivative with reduced cardiotoxicity, registered in Poland for monotherapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL) in the third or fourth line of treatment. As R/R population is difficult to treat due to comorbidities including circulatory system pathologies we evaluate polish patients treated with PIX. This is the first real life study evaluating patients treated with PIX in Poland with emphasis on efficacy and cardiovascular toxicity.</p><p><strong>Methods: </strong>The retrospective study assessing safety and effectiveness of PIX administered in patients with aggressive de novo or transformed B-NHL [according to the Revised European American Lymphoma (REAL) and World Health Organization (WHO) classifications], who relapsed or were refractory to two or three previous lines of chemotherapy regimens, including at least one standard anthracycline-based regimen. Patients who did not remain sensitive to anthracyclines were excluded from this study. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), complete response (CR) rate, overall response rate (ORR) and safety.</p><p><strong>Results: </strong>The data of 17 patients were collected in 6 study sites. The median age was 72 (range: 58-82) years old with male predominance (65%). In observed group10 patients had diffuse large B-cell lymphoma (DLBCL), 6 mantle cell lymphoma (MCL) and 1 patient had Richter syndrome. Five subjects responded to PIX (CR 2 and partial response 3)-ORR was 29%. The median of PFS was 12.9 months [standard error (SE) 2.2; 95% confidence interval (CI): 8.5, 17.2]. The median of survival time was 22.6 months (SE 7.3; 95% CI: 8.3, 36.8). The PIX compliance was good, with incidental dose omission or delay. The main reason for discontinuation was disease progression.</p><p><strong>Conclusions: </strong>Administration of PIX to patients with R/R aggressive B-NHL treated with multiple lines of chemotherapy containing maximal cumulative dose of anthracycline and with numerous concomitant diseases may be a potentially valuable therapeutic option but data from larger clinical studies will help in confirming PIX as an effective and safe option.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148807895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can recurrence-free survival replace overall survival for resectable esophageal cancer?","authors":"Jane E Rogers, Jaffer A Ajani","doi":"10.21037/cco-2026-1-0002","DOIUrl":"https://doi.org/10.21037/cco-2026-1-0002","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148223575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toxicity management in thoracic chemoradioimmunotherapy: pirfenidone for low grade pneumonitis and lung fibrosis.","authors":"Franz Zehentmayr, Elvis Ruznic, Raphaela Moosbrugger, Brane Grambozov","doi":"10.21037/cco-2026-1-0019","DOIUrl":"https://doi.org/10.21037/cco-2026-1-0019","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148223628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing media composition for patient-derived organoids in ovarian cancer: a narrative review.","authors":"Kattreen Hanna, Mayerly Castrillón Sánchez, Gabriel Levin, Gaëlle Akiki, Basile Tessier-Cloutier, Shuk On Annie Leung","doi":"10.21037/cco-2026-1-0013","DOIUrl":"https://doi.org/10.21037/cco-2026-1-0013","url":null,"abstract":"<p><strong>Background and objective: </strong>Patient-derived organoids (PDOs) are emerging as powerful ex vivo models for studying ovarian cancer (OC) biology and drug response. However, success rates for establishing OC PDOs remain low, partly due to heterogeneous media formulations and inconsistent definitions of \"success\". This review aims to compare media compositions, summarize derivation efficiencies across studies, and identify cross-cancer insights that may inform optimization of OC PDO culture conditions.</p><p><strong>Methods: </strong>A structured PubMed search was performed using the terms \"ovarian cancer PDOs\" and \"ovarian cancer patient-derived organoids\". Studies were included if they were primary research articles, published from 2018 onward, did not use commercial PDO kits, and provided detailed descriptions of media composition and culture methods. Ten studies met all criteria and were analyzed for media components, tissue sources, derivation efficiencies, and definitions of success.</p><p><strong>Key content and findings: </strong>Across 10 foundational studies, success rates ranged from 13% to 65%, influenced by tissue type, histology, and variable definitions of success. Media compositions shared core components such as advanced DMEM/F12, B27, GlutaMAX, nicotinamide, and A83-01, but differed significantly in Wnt/BMP modulators, growth factors, hormonal additives, and inhibitors. Evidence suggests that high-Wnt conditions support PDOs in colorectal and pancreatic cancers but may hinder long-term growth in HGSOC. Cross-cancer comparisons highlighted potentially transferable strategies, particularly from TP53-mutant pancreatic and colorectal PDO systems.</p><p><strong>Conclusions: </strong>OC PDO establishment remains challenging due to inconsistent culture conditions and varying success definitions. Standardizing media formulations, harmonizing reporting practices, and applying insights from other TP53-mutant cancers may improve reproducibility and clinical applicability. Tailored, subtype-specific optimization is likely necessary to enhance PDO derivation and utility in precision oncology.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 3","pages":"43"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venetoclax with intensive chemotherapy in acute myeloid leukemia.","authors":"Logan Shaver, Omer Jamy","doi":"10.21037/cco-2026-1-0005","DOIUrl":"https://doi.org/10.21037/cco-2026-1-0005","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 3","pages":"54"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis.","authors":"Bannawich Sapapsap, Sirapratch Champarhorm, Anchana Pongpun, Nattapong Kanchana, Jittipon Tantivit, Nattawut Leelakanok","doi":"10.21037/cco-2026-1-0018","DOIUrl":"10.21037/cco-2026-1-0018","url":null,"abstract":"<p><strong>Background: </strong>Trifluridine/tipiracil (TAS-102) and regorafenib are approved and widely utilized as later-line treatment options for patients with metastatic colorectal cancer (mCRC). However, the optimal sequence between these agents remains unclear. We conducted a systematic review and meta-analysis to compare the efficacy and safety of two treatment sequences: TAS-102 followed by regorafenib (TR) versus regorafenib followed by TAS-102 (RT) in patients with mCRC who had previously failed chemotherapy.</p><p><strong>Methods: </strong>This study was registered with PROSPERO (CRD42024622437). We systematically searched six databases (PubMed, Scopus, CINAHL, ScienceDirect, medRXiv, and OpenGrey) up to June 1, 2025. Risk of bias was assessed using the ROBINS-I tool. Pooled estimates with 95% confidence intervals (CIs) were calculated using a random-effects model. For studies lacking hazard ratios (HRs), we estimated the HRs using the ratio of median survival times. Publication bias was evaluated with a funnel plot.</p><p><strong>Results: </strong>Thirteen observational studies with moderate to critical risk of bias were included. No significant difference was found in overall survival (OS) (HR =1.04, 95% CI: 0.86-1.25, I2=72%) or progression-free survival (PFS) (HR =1.34, 95% CI: 0.77-2.34, I2=92%) between the TR and RT groups. The RT group had a higher disease control rate (DCR) (33.1% vs. 28.0%) and tended to have more adverse events (AEs).</p><p><strong>Conclusions: </strong>OS and PFS outcomes were comparable between patients treated with TAS-102 followed by regorafenib and those receiving the reverse sequence. Although the RT group was associated with a slightly higher DCR, this was accompanied by a trend toward increased AEs.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 3","pages":"42"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toxicity management in thoracic chemoradioimmunotherapy: pirfenidone for low grade pneumonitis and lung fibrosis.","authors":"Franz Zehentmayr, Elvis Ruznic, Raphaela Moosbrugger, Brane Grambozov","doi":"10.21037/cco-2026-1-0019","DOIUrl":"https://doi.org/10.21037/cco-2026-1-0019","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 3","pages":"55"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination therapy in sarcomas and the challenges of heterogeneity.","authors":"Emine Hatipoglu, Robin L Jones","doi":"10.21037/cco-2026-1-0017","DOIUrl":"https://doi.org/10.21037/cco-2026-1-0017","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 3","pages":"48"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age, endocrine therapy persistence, and recurrence risk in hormone receptor-positive early breast cancer: clarifying a long-standing clinical question.","authors":"Marcus Schmidt","doi":"10.21037/cco-2025-1-183","DOIUrl":"https://doi.org/10.21037/cco-2025-1-183","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 3","pages":"51"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology, diagnosis, and treatment of primary pulmonary mucosa-associated lymphoid tissue lymphoma.","authors":"Gabriele Sapuppo, Sara Frazzetto, Maria Cristina Pirosa, Emanuele Zucca","doi":"10.21037/cco-2025-1-134","DOIUrl":"https://doi.org/10.21037/cco-2025-1-134","url":null,"abstract":"<p><p>Primary pulmonary B-cell lymphomas are rare, accounting for <1% of non-Hodgkin lymphomas (NHLs) and 3-4% of extranodal NHL. Extranodal marginal zone lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT; pulmonary MALT lymphoma), arising from bronchus-associated lymphoid tissue (BALT), represents over 80-90% of cases. These tumors typically develop as a result of chronic antigenic stimulation in the setting of persistent inflammation, due to infection, or autoimmune disease. Two main pathogenetic phases are recognized in their development: an antigen-dependent phase, in which clonal B-cell expansion and survival are driven by ongoing exposure to specific antigens, and an antigen-independent phase, in which B-cell proliferation becomes autonomous due to cytogenetic and molecular alterations. Clinically, pulmonary MALT lymphoma has an indolent course and is often detected incidentally; when symptoms occur, they are non-specific. Radiologic findings include consolidations, nodules, or masses. Diagnosis relies on histopathology, immunophenotyping (CD20+, light-chain restriction, CD5-/CD10-/cyclin D1-), and molecular studies. Most patients present at early Ann Arbor stages, with a 5-year overall survival exceeding 90%. Management should be tailored to the disease stage, symptoms, comorbidities, and patient preferences. A watch-and-wait approach is appropriate for asymptomatic patients without treatment indications. Radiotherapy is highly effective for localized disease, while rituximab alone or with chemotherapy, particularly bendamustine-rituximab, is preferred for advanced symptomatic disease. Bruton's tyrosine kinase inhibitors have shown efficacy in relapsed or refractory cases. This review summarizes the epidemiology, pathogenesis, clinicopathologic features, diagnosis, and evolving treatment strategies of pulmonary MALT lymphoma, highlighting its favorable prognosis and unique immunobiological origin.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 3","pages":"46"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}